During the past decade, Centrum Onkologii im. prof. Franciszka Lukaszczyka w Bydgoszczy conducted 34 clinical trials. In the 10-year time frame, 34 clinical trials started and 15 clinical trials were completed, i.e. on average, 44.1% percent of trials that started reached the finish line to date. In the past 5 years, 23 clinical trials started and 11 clinical trials were completed. i.e. 47.8% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Centrum Onkologii im. prof. Franciszka Lukaszczyka w Bydgoszczy" #1 sponsor was "Hoffmann-La Roche" with 10 trials, followed by "Janssen Research & Development, LLC" with 9 trials sponsored, "Gilead Sciences" with 3 trials sponsored, "Bayer" with 2 trials sponsored and "Merck Sharp & Dohme LLC" with 2 trials sponsored. Other sponsors include 8 different institutions and companies that sponsored additional 17 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Centrum Onkologii im. prof. Franciszka Lukaszczyka w Bydgoszczy" #1 collaborator was "Breast International Group" with 2 trials as a collaborator, "Genentech, Inc." with 2 trials as a collaborator, "Astellas Pharma Global Development, Inc." with 1 trials as a collaborator, "Austrian Breast and Colorectal Cancer Group" with 1 trials as a collaborator and "BeiGene" with 1 trials as a collaborator. Other collaborators include 0 different institutions and companies that were collaborators in the rest 10 trials.

According to Clinical.Site data, the most researched conditions in "Centrum Onkologii im. prof. Franciszka Lukaszczyka w Bydgoszczy" are "Breast Cancer" (4 trials), "Carcinoma, Non-Small-Cell Lung" (4 trials), "Colorectal Cancer" (2 trials), "Gastric Cancer" (2 trials) and "Glioblastoma Multiforme" (2 trials). Many other conditions were trialed in "Centrum Onkologii im. prof. Franciszka Lukaszczyka w Bydgoszczy" in a lesser frequency.

Most popular intervention types in "Centrum Onkologii im. prof. Franciszka Lukaszczyka w Bydgoszczy" are "Drug" (35 trials), "Other" (4 trials), "Radiation" (4 trials), "Biological" (2 trials) and "Procedure" (2 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (12 trials), "Carboplatin" (5 trials), "Cisplatin" (5 trials), "Docetaxel" (5 trials) and "Pembrolizumab" (5 trials). Other intervention names were less common.

The vast majority of trials in "Centrum Onkologii im. prof. Franciszka Lukaszczyka w Bydgoszczy" are 32 trials for "All" genders, 5 trials for "Male" genders and 2 trials for "Female" genders.

Currently, there are NaN active trials in "Centrum Onkologii im. prof. Franciszka Lukaszczyka w Bydgoszczy". undefined are not yet recruiting, 16 are recruiting, 5 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 12 completed trials in Centrum Onkologii im. prof. Franciszka Lukaszczyka w Bydgoszczy, undefined suspended trials, and 6 terminated clinical trials to date.

Out of the total trials that were conducted in Centrum Onkologii im. prof. Franciszka Lukaszczyka w Bydgoszczy, 0 "Phase 1" clinical trials were conducted, 13 "Phase 2" clinical trials and 23 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 1 trials, and there were also 1 trials that are defined as “Not Applicable".

Centrum Onkologii im. prof. Franciszka Lukaszczyka w Bydgoszczy has several departments that took part in Clinical trials: "Centrum Onkologii w Bydgoszczy; Oddzial Kliniczny Onkologii" - 3 trials, "Centrum Onkologii im. Prof. Franciszka Łukaszczyka; Ambulatorium Chemioterapii" - 3 trials